Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 1 , Pages 73-78 , July 2009

Spice active principles as the inhibitors of human platelet aggregation and thromboxane biosynthesis

Received 7 March 2008 ,Revised 7 January 2009 ,Accepted 23 April 2009.

References 

  1. Cecil RP, Susan H, Eleftherios PD, George S, David MG. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications of protection against coronary heart disease. Clin. Chim. Acta. 1995;235:207–219
  2. Ruggeri ZM. Platelets in atherothrombosi. Nat. Med. 2002;8:1127–1234
  3. Buhl AM, Johnson NL, Dhanashekaran N, Johnson GL. Gα12 and Gβ13 stimulate rho-dependent stress fiber formation and focal adhesion assembly. J. Biol. Chem. 1995;270:24631–24634
  4. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in Gαq-deficient mice. Nature. 1997;389:183–186
  5. Patrono C, Coller B, Fitz Gerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S
  6. Antithrombotic Trialists’ Collaboration (ATC). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002;324:71–86
  7. Lepäntalo, A., individual variation in in vitro efficacy of antiplatelet medication—aspirin and clopidogrel. Academic Dissertation, Department of Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki, Finland, 2007.
  8. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331–2336
  9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 2003;41:961–965
  10. Golanski J, Golanski R, Iwaszkiewicz A, Chlopicki S, Gresner P, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient. Impact on the monitoring of aspirin antiplatelet therapy. Ther. Drug Monit. 2005;27:484–490
  11. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet. 1993;342:1007–1011
  12. Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am. J. Clin. Nutr. 2005;81:292S–297S
  13. Rein D, Paglieroni TG, Wun T, Pearson DA, Schmitz HH, Gosselin R, et al. Cocoa inhibits platelet activation and function. Am. J. Clin. Nutr. 2000;72:30–35
  14. Freedman JE, Parker C, Li L, Perlman JA, Frei B, Ivanov V, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001;103:2792–2798
  15. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot. Essent. Fatty Acids. 1995;52:223–227
  16. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet activating factor-and arachidonic acid mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem. Pharmacol. 1999;58:1167–1172
  17. Srivastava KC, Malhotra N. Acetyl eugenol, component of oil of cloves (Syzigium aromaticum) inhibits platelet aggregation and alters arachidonic acid metabolism in human blood platelets. Prostaglandins Leukot. Essent. Fatty Acids. 1991;42:73–81
  18. Chen SJ, Wang MH, Chen IJ. Antiplatelet and calcium inhibitory properties of eugenol and sodium eugenol acetate. Gen. Pharmacol. 1996;27:629–6333
  19. Satyaprasad N, Raghavendra R, Lokesh BR, Naidu KA. Spice phenolics inhibit human PMNL 5-lipoxygenase. Prostaglandins Leukot. Essent. Fatty Acids. 2004;70:521–528
  20. Raghavendra H, Diwakar BT, Lokesh BR, Naidu KA. Eugenol active principle of clove inhibit 5-lipoxygenase and leukotriene-C4 in human PMNLs. Prostaglandins Leukot. Essent. Fatty Acids. 2006;74:23–27
  21. Hamilton JG, Karol RJ. High performance liquid chromatography (HPLC) of arachidonic acid metabolites. Prog. Lipid Res. 1982;21:155–170
  22. Brouard C, Pascaud M. Effects of moderate dietary supplementations with n-3 fatty acids on macrophage and lymphocyte phospholipids and macrophage eicosanoid synthesis in the rat. Biochem. Biphys. Acta. 1990;1047:19–20
  23. David RJ, Barbara B. Analysis of Cardiac membrane phospholipids peroxidation kinetics as malondialdehyde: non-specificity of thiobarbituric acid-reactivity. Lipids. 1988;23:452–458
  24. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemostasis. 2003;1:1710–1713
  25. Takenaga M, Hirai A, Terano T, Tamura Y, Kitgawa H, Yoshida S. In vitro effect of cinnamaldehyde, a main component of cinnamoni cortex. Chem. Pharm. Bull. 1975;23:941–947
  26. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr. Opin. Cell Biol. 1994;6:695–704
  27. Jingqun H, Siwang W, Xiaoxing L, Yanhua X, Xinyou S. Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents. Thromb. Res. 2007;119:337–342
  28. Srinivasan K. Role of spices beyond food flavoring: nutraceuticals with multiple health effects. Food Rev. Int. 2005;21:167–188

PII: S0952-3278(09)00062-3

doi: 10.1016/j.plefa.2009.04.009

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 1 , Pages 73-78 , July 2009

Article Tools

* Image Usage & Resolution